Characteristics and distribution of clinical manifestations in the Italian cohort of patients with APS included in the study. Values are n (%) unless otherwise specified.
| Patient Characteristics or Clinical Manifestations | PAPS | SAPS |
|---|---|---|
| Patients, n | 15 | 25 |
| Age, yrs, median (range) | 32 (20–62) | 35 (12–76) |
| Women | 14 (93) | 24 (96) |
| Fetal losses | 3 (20) | 5 (20) |
| Anti-CL IgG | 10 (67) | 15 (60) |
| Anti-CL IgM | 9 (60) | 16 (64) |
| Anti-β2-GP1 IgG | 7 (88) | 10 (40) |
| Anti-β2-GP1 IgM | 7 (50) | 9 (36) |
| ANA | 8 (53) | 25 (100) |
| LA | 10 (71) | 17 (68) |
| Thrombosis venous | 8 (53) | 17 (68) |
| Thrombosis arterial | 7 (47) | 6 (24) |
| C3 low level | 0 (0) | 11 (44) |
APS: antiphospholipid syndrome; PAPS: primary APS; SAPS: secondary APS; CL: cardiolipin; Ig: immunoglobulin; β2-GP1: β2 glycoprotein 1; ANA: antinuclear antibodies; LA: lupus anticoagulant; C3: complement factor 3.